Overview
Scorpion Therapeutics develops precision oncology drugs targeting validated cancer drivers and advances them through R&D partnerships. Its compounds are designed to interact with specific cancer targets and optimize potency, selectivity, and drug-like properties using chemistry, proteomics, computation, and machine learning, with commercialization handled via collaborations. The company differentiates itself by integrating deep multidisciplinary expertise and pursuing milestone/royalty partnerships with established pharma players rather than relying solely on internal development. Its goal is to deliver fast, targeted, and potent cancer therapies that reach patients worldwide.
Work here?Claim your company
Simplify's take
What believers are saying
- Lilly’s 2026 transaction validates Scorpion’s discovery engine and raises partner interest immediately.
- Pierre Fabre’s 2023 deal still funds global EGFR development and preserves U.S., Canada, Japan rights.
- Scorpion’s 2026 pipeline update shows breadth beyond PI3Kα, with partnered and wholly-owned programs.
What critics are saying
- Lilly’s $2.5 billion STX-478 license strips Scorpion’s flagship and cash-generating centerpiece, closing 2026.
- The remaining company depends on two EGFR programs, both early-stage and clinically unproven.
- A failed STX-721 or STX-241 readout kills the spinout’s value and financing leverage.
What makes Scorpion Therapeutics unique
- Scorpion’s Precision Oncology 2.0 built mutant-selective PI3Kα chemistry, not me-too oncology assets.
- STX-478 targets PI3Kα-mutant tumors with CNS penetration and high mutant selectivity, per 2026 data.
- STX-721 and STX-241 attack resistant EGFR mutations, including exon 20 and C797S.
Help us improve and share your feedback! Did you find this helpful?
